• Age ≥ 18 years old;

• Histologically confirmed diagnosis of NSCLC;

• Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;

• Treatment naïve;

• Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1);

• Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy;

• Informed consent to participate in the study;

• Age ≥ 18 years old;

• Histologically confirmed diagnosis of SCLC；

• Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition;

• ECOG PS of 0-1;

• Treatment naïve;

• Presence of at least one measurable lesion according to the RECIST v1.1 ;

• Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy;

• Informed consent to participate in the study;

• Age ≥18 years old;

• Pathologically diagnosed as NSCLC;

• Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition;

• At least one measurable lesion can be evaluated according to the RECIST v1.1;

• Treatment naïve;

• Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy as neoadjuvant therapy;

• Cardiopulmonary function can withstand surgery;

• Informed consent to participate in the study.

• Age ≥ 18 years old;

• Pathologically diagnosed as NSCLC;

• Pathologically stage confirmed as early stage of IA-IIIA;

• Available for tumor tissue samples;

• Treatment naïve;

• Receiving radical surgery;

• Informed consent to participate in the study;

• Age ≥ 18 years old;

• Histologically confirmed diagnosis of NSCLC;

• Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;

• ECOG PS of 0-1;

• Treatment naive;

• Presence of at least one measurable lesion according to the RECIST v1.1;

• Receiving targeted therapy or combination with chemotherapy;

• Informed consent to participate in the study;

• Driver gene-positive.